CoChat
Sign Up
Cited by 237Breast Cancer Treatment StudiesBreast Lesions and CarcinomasStatistical Methods in Epidemiology

The DOI matches its Crossref record; 23 of the 24 references it cites were found in a registry or an index.

Time-dependence of hazard ratios for prognostic factors in primary breast cancer

Hilsenbeck, Susan G., Ravdin, Peter M., de Moor, Carl A., Chamness, Gary C., Osborne, C. Kent, Clark, Gary M.·1998·Breast Cancer Research and Treatment
DOI 10.1023/a:1006133418245
Open this paper in CoChat — free account

Abstract

Some prognostic factors, such as steroid receptors, appear strongly related to outcome in early studies with short follow-up, but as follow-up matures the relationships appear to weaken. We investigated this phenomenon for several factors (tumor size, axillary lymph nodes, S-phase fraction, estrogen receptor (ER) status, and adjuvant therapy) in a large sample of breast cancer cases (N=2,873) with up to 17 years of follow-up for disease-free survival (DFS). Subjects in the study were identified from patients who had hormone receptor assays performed in our laboratory. Analysis of DFS included fitting a multivariate Cox proportional hazards model, testing for nonproportionality, and examining diagnostic plots. The assumption of proportional hazards was violated for several factors including ER, tumor size, and S-phase fraction. For ER, the hazard ratio was initially less than 1.0, indicating a good effect on prognosis, but increased at later times to values greater than 1.0, indicating a bad effect on prognosis. In contrast, the hazard ratios for tumor size and S-phase were initially high and decreased asymptotically toward 1.0 over time. Analysis of p53 expression in a subset of cases yielded qualitatively similar results. We conclude that several standard prognostic factors (ER, tumor size, S-phase fraction) and possibly other investigational factors have important but nonproportional effects on hazard. It is likely that violation of proportional hazards is common and not limited to breast cancer. Failure to recognize violations of proportional hazards can lead to both over- and under-estimation of the effects of important prognostic factors.

Overview

Integrity signals

Registry

Crossref · 10.1023/a:1006133418245

Cites

23 of 23 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Expression of estrogen receptor (ER)-α is a favorable prognostic factor.

    “Elevated serum levels of estradiol are weakly associated with increased breast cancer risk (62), while expression of estrogen receptor (ER)-α is a favorable prognostic factor (63).”

    From Diabetes and Cancer (2010) · cites this paper as [63]

Citations

Cites

Flagged first, then by citations

1 of the 24 references couldn’t be matched to a known paper.

Research works printed but not linked: 1

  1. Ulm K, Jänicke F, Pache L, Dannegger F: Change in prognostic impact of uPA and PAI-1 in node-negative breast cancer patients during the follow-up. Breast Cancer Res Treat 37(S):59, 1996

Cited by

Sorted by citations

Related

Metadata

Authors
Hilsenbeck, S. G., Ravdin, P. M., de Moor, C. A., Chamness, G. C., Osborne, C. K., & Clark, G. M.
Affiliations
The University of Texas at San Antonio Health Science Center (US)
ORCID
Venue
Breast Cancer Research and Treatment
Publisher
Springer Science and Business Media LLC
Published
1998-11
Volume
52
Issue
1-3
Pages
227-237
ISSN
  • 0167-6806 (ISSN-L)
  • 1573-7217
DOI
10.1023/a:1006133418245
OpenAlex
W2019665138
Cited by
237
References
24
Citations by year
2026: 1 · 2025: 4 · 2024: 2 · 2023: 1 · 2022: 3 · 2021: 7 · 2020: 2 · 2019: 7 · 2018: 8 · 2017: 10 · 2016: 10 · 2015: 10 · 2014: 14 · 2013: 10 · 2012: 10
FWCI
2.38
Type
journal article
Language
en
Open access
closed
Licence
Locations
  • Breast Cancer Research and Treatment (publishedVersion)
  • PubMed (publishedVersion)
Funders
National Cancer Institute (P30CA 54174, P30CA054174, P01CA030195, P01_CA30195)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
  • Health Sciences › Medicine › Pathology and Forensic Medicine › Breast Lesions and Carcinomas
  • Physical Sciences › Mathematics › Statistics and Probability › Statistical Methods in Epidemiology
Keywords
primary breast cancer, prognostic factors, proportional hazards assumption violation, estrogen receptor status, tumor size, S-phase fraction, p53 expression, adjuvant therapy, axillary lymph nodes, disease-free survival, hormone receptor assays
MeSH terms
Adult, Aged, Breast Neoplasms, Female, Humans, Middle Aged, Prognosis, Receptors, Estrogen, Time Factors, Proportional Hazards Models, Tumor Suppressor Protein p53, S Phase, Disease-Free Survival

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review